(2-Pack) CJC-1295 / IPAMORELIN – 10mg
Related Products
Peer-Reviewed Literature
Related Studies
Peer-Reviewed Literature
Related Studies
Ipamorelin, the First Selective Growth Hormone Secretagogue
European Journal of Endocrinology
Foundational paper establishing ipamorelin as a selective GHS-R1a agonist. Unlike GHRP-2 and GHRP-6, ipamorelin does not stimulate ACTH or cortisol, making it uniquely selective.
Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers
Pharmaceutical Research
Dose-escalation trial demonstrated ipamorelin produces a GH release episode peaking at 0.67 hours with terminal half-life of 2 hours across five dose levels in healthy male volunteers.
Ipamorelin Induces Longitudinal Bone Growth in Rats
Growth Hormone & IGF Research
Ipamorelin dose-dependently increased longitudinal bone growth rate from 42 to 52 µm/day with pronounced dose-dependent effects on body weight gain in adult female rats.
Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor I Secretion by CJC-1295 in Healthy Adults
Journal of Clinical Endocrinology & Metabolism
Single injection of CJC-1295 produced dose-dependent GH increases of 2–10 fold sustained for 6+ days and IGF-I elevations of 1.5–3 fold for 9–11 days, with half-life of 5.8–8.1 days.
Pulsatile Secretion of Growth Hormone Persists During Continuous Stimulation by CJC-1295
Journal of Clinical Endocrinology & Metabolism
CJC-1295 increased trough and mean GH secretion and IGF-I production while preserving physiological GH pulsatility — distinguishing it from continuous GH replacement.
Activation of the GH/IGF-1 Axis by CJC-1295 Results in Serum Protein Profile Changes in Normal Adult Subjects
Growth Hormone & IGF Research
Proteomic analysis of sera from 11 healthy men demonstrated significant protein profile changes reflecting GH/IGF-1 axis activation one week after CJC-1295 injection.